Related Experiment Videos
[Therapy with vitamin D and D-metabolites]
Schweizerische Medizinische Wochenschrift
|February 28, 1981
Summary
New vitamin D therapies utilize potent metabolites for conditions like chronic renal failure and hypoparathyroidism. Careful monitoring of calcium levels is crucial for patients receiving vitamin D compounds to prevent excessive dosage.
Area of Science:
- Endocrinology
- Metabolic Bone Disease
Background:
- The vitamin D endocrine system's elucidation offers novel therapeutic strategies.
- Traditional vitamin D deficiency treatment remains unchanged, focusing on vitamin D itself.
Purpose of the Study:
- To outline appropriate uses for vitamin D metabolites and pharmacological doses.
- To emphasize the need for careful patient monitoring during vitamin D therapy.
Main Methods:
- Review of current vitamin D therapy approaches.
- Analysis of indications for vitamin D metabolites like 1,25-dihydroxycholecalciferol (1,25-DHCC) and 1 alpha-CC.
Main Results:
- 1,25-DHCC and 1 alpha-CC are indicated for hypocalcemia due to impaired 1-hydroxylation (renal failure, hypoparathyroidism).
- Promising results observed in treating hypophosphatemic rickets with 1-hydroxylated compounds.
- Vitamin D metabolites and high-dose vitamin D act as hormone substitutions requiring monitoring.
Conclusions:
- Specific vitamin D metabolites should be reserved for conditions with impaired 1-hydroxylation.
- Further research is warranted for using 1-hydroxylated compounds in hypophosphatemic rickets.
- Close monitoring of serum and urine calcium is essential for all patients on vitamin D therapy, especially those with sarcoidosis due to hypercalcemia risk.